000			03228nam a22004335i 4500
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _0http://viaf.org/viaf/148105729 _9106996
999			_c99865 _d99865 _x1
001			99865
003			DE-He213
005			20230110040154.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180801s2018 gw | s |||| 0|eng d
020			_a9783319914398
024	7		_a10.1007/978-3-319-91439-8 _2doi
040			_aES-MaUEC _bspa _dES-MaUEC
050		4	_aRS431.A64 2018 EB
245	1	0	_aSmall Molecules in Hematology _cedited by Uwe M. Martens.
250			_a3rd edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (VIII, 294 páginas 28 ilustraciones, 17 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	1		_aRecent Results in Cancer Research, _x0080-0015 ; _v212
490	0		_aMedicine (Springer-11650)
505	0		_aImatinib -- Dasatinib -- Nilotinib -- Bosutinib -- Ponatinib -- Ruxolitinib -- Ibrutinib -- Lenalidomide -- Pomalidomide -- Enasidenib -- Midostaurin -- Alectinib -- Osimertinib -- Venetoclax -- Idelaslisib -- Carfilzomib -- Acalabrutinib.
520	3		_aThis book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.
988			_aSpringer_Medicine_2018
650		7	_aAntineoplásicos _2embne _9405304
650		7	_9140122 _aHematología _2embne
650		7	_aOncología _2embne _9139207
700	1		_aMartens, Uwe M. _eeditor literario _0http://id.loc.gov/authorities/names/nb2009032421 _0http://viaf.org/viaf/25758710 _988893
776	0	8	_iEdición impresa: _z9783319914381
776	0	8	_iEdición impresa: _z9783319914404
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-91439-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2019 _dz _ea _feng _ggw _h0